Marchiafava–Bignami Disease Presenting as Acute Psychosis

Sir,

Marchiafava–Bignami disease (MBD) is a rare neurological disorder of unknown etiology, afflicting mostly middle or elderly males with a history of chronic alcohol consumption or chronic malnutrition.[1–3] There are <300 described cases in the literature and many cases go undiagnosed.[4] Its pathological hallmark is symmetrical demyelination and necrosis of the central part of the corpus callosum.[5] The disease has varied neuropsychiatric manifestations which include agitation, confusion, delirium, rigidity, dysarthria, mutism, split-brain syndrome, incontinence, dementia, psychotic symptoms, and gaze palsy.[6,7]

We report a rare presentation of MBD in a 32-year-old male having a history of heavy alcohol consumption who presented with persecutory delusion, auditory hallucinations, dysarthria, and urinary incontinence and whose psychotic symptoms responded to olanzapine.

REFERENCES
1. Litvan I, Mega MS, Cummings JL, Fairbanks L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 1996;47:1184-9.
2. Schrag A, Sheikh S, Quinn NP, Lees AJ, Selai C, Mathias C, et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord 2010;25:1077-81.
3. Gerstenecker A, Duff K, Mast B, Litvan I; ENGEE-PSP Study Group. Behavioral abnormalities in progressive supranuclear palsy. Psychiatry Res 2013;210:1205-10.
4. Madhusoodanan S, Wilkes V, Campbell RP, Serper M, Essuman EK, Brenner R. Psychiatric symptoms of progressive supranuclear palsy: A case report and brief review. Neuropsychiatr 2014;4:27-32.
5. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders – Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization; 1992.
6. Kim WH, Lee YS, Jung SH, Choi HJ, Lee MJ, Kang MH, et al. Major depressive disorder preceding the onset of progressive supranuclear palsy. Psychiatry Investig 2009;6:112-4.
7. Quante A, Jakob F, Wolf J. Depression preceding the onset of progressive supranuclear paralysis: A case report. J Neuropsychiatry Clin Neurosci 2008;20:247-8.
8. Lubarsky M, Juncos JI. Progressive supranuclear palsy: A current review. Neurologist 2008;14:79-88.
9. Pillon B, Dubois B, Ploska A, Agid Y. Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsy. Neurology 1991;41:634-43.
10. Litvan I, Agid Y, Caline D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-richardson-olszewski syndrome): Report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
11. van Meerkerk-Aannen PJ, de Vroege L, Khaso D, Foruz A, van Asseldonk JT, van der Feltz-Cornelis CM, et al. La belle indifférence revisited: A case report on progressive supranuclear palsy misdiagnosed as conversion disorder. Neuropsychiatr Dis Treat 2017;13:2057-67.
12. Warren NM, Burn DJ. Progressive supranuclear palsy. Pract Neurol 2007;7:16-23.
CASE REPORT

A 32-year-old unmarried Indian male presented with complaints of suspiciousness, decreased sleep, and violent behavior for 15 days and episodes of urinary incontinence with difficulty in speaking for 10 days. He feared being killed and poisoned, so he confined himself to his room and refused to eat. The patient had a history of heavy alcohol consumption since the age of 15 (750 ml whiskey daily, 42% alcohol by volume). There was no significant medical or psychiatric history and no significant family history. Two months before the presentation, the patient was admitted for alcohol detoxification and he was abstinent since then. On examination, he was malnourished, disheveled, verbally abusive, and anxious. Persecutory delusions and auditory hallucinations were present. He was conscious, alert, and oriented to time, place, and person. There were no signs of meningeal irritation, and the vitals were stable. Neurological evaluation revealed dysarthria and hypertonicity of limbs. He had deranged liver transaminase enzymes (aspartate transaminase – 143.2 IU/L, alanine transaminase – 65.7 IU/L), macrocytosis (MCV – 108 fL), reduced serum Vitamin B1 level, and Grade 1 fatty liver.

Neurology consultation was sought, and a noncontrast computerized tomographic scan of the brain revealed hypodensity in the region of the corpus callosum. Magnetic resonance imaging scan showed a T2-hyperintense lesion, with restricted diffusion of the corpus callosum, without swelling or enhancement. A diagnosis of MBD was made. He was started on tablet olanzapine 5 mg twice daily, 300 mg oral thiamine, 5 mg of oral folic acid, and tablet lorazepam 2 mg at night.

After 4 days, the patient was no longer violent, sleep was improved, and delusion and hallucination subsided. However, dysarthria, episodes of urinary incontinence, and hypertonicity of limbs persisted. Over the next 10 days, the patient showed improvement, tablet lorazepam was stopped, and olanzapine was reduced to 5 mg once daily at night. Subsequently, he was discharged and followed up for 6 months, during which he was maintaining well on 5 mg olanzapine once daily and 300 mg oral thiamine and had no psychotic phenomena, but his neurological symptoms persisted.

DISCUSSION

MBD is a rare disorder generally associated with chronic alcohol consumption and has a varying clinical course. Its acute form can present with impaired consciousness, seizure, and coma while its subacute form presents with mental confusion, emotional distress, behavioral abnormality, and psychosis.[5] Augusto et al.[8] reported visual hallucinations in a 52-year-old woman with chronic alcoholism and MBD, and Hui et al.[9] described, in a 41-year-old man, persecutory delusion and auditory hallucinations which did not respond to 15 mg of haloperidol or 6 mg of risperidone. Our patient had a relatively early onset of MBD. His clinical presentation was dominated by the presence of psychotic phenomena which improved considerably on 10 mg of olanzapine and was well maintained on 5 mg of olanzapine in the 6-month follow-up. He tolerated olanzapine without significant adverse effects. Olanzapine has been shown to be particularly useful in psychosis with comorbid substance abuse, and these patients have better outcomes and low risk of extrapyramidal adverse effects.[10]

Since early recognition and treatment may provide a favorable outcome, MBD should be included in the differential diagnosis of patients with heavy alcohol consumption presenting with psychotic phenomena. Although there is no established treatment of MBD, the use of thiamine and folic acid is recommended.[5] While earlier studies have questioned the role of antipsychotics in managing the psychotic phenomena in MBD, our patient benefited considerably, possibly because of early detection.

Declaration of patient consent

The authors certify that they have obtained patient consent form. In the form, the patient has given his consent for all of his clinical information to be reported in the journal. The patient understands that his name and initials will not be published and due efforts will be made to conceal his identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Azmi Naaz, Abid Rizvi, Mohammad Amir Usmani

Department of Psychiatry, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India, 1Department of Psychiatry, Jamaica Hospital Center, Jamaica, New York, USA

Address for correspondence: Dr. Abid Rizvi
Department of Psychiatry, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh - 202 002, Uttar Pradesh, India.
E-mail: abidrizvi021@gmail.com

REFERENCES

1. Jorge JM, Gold M, Sternman D, Prabhakaran K, Yelom J. Marchiafava-Bignami disease in a trauma patient. J Emerg

Ind. J Psychol Med | Vol 40 | Issue 5 | September-October 2018
Lacosamide Precipitated Neutropenia in a Patient with Bipolar Disorder and Comorbid Epilepsy

Sir,

Epilepsy is common in patients with bipolar disorder.[1] While anti-epileptic agents are commonly used for the treatment of bipolar disorder, one needs to be cautious about their side effects when they are used in combination with other psychotropic medications, due to the possibility of additive side effects. In this case report, we describe a patient with bipolar disorder and complex partial seizures, on treatment with clozapine, who developed neutropenia after initiating lacosamide.

CASE REPORT

Mr. A, a 20-year-old male, had a global developmental delay and was diagnosed as having mild intellectual developmental disorder. From the age of 13 years, he had multiple episodes of mania and was diagnosed as having bipolar affective disorder (International Classification of Disorders-10). In view of treatment resistance, he was on treatment with clozapine 200 mg/day for 2 years and had achieved partial remission of symptoms. He also had poorly controlled complex partial seizures with secondary generalization since the age of 5 years. He had a poor response to phenytoin, carbamazepine, and levetiracetam and was on valproate 1000 mg/day and clobazam 10 mg/day with a partial response. In view of the poor control of epilepsy, lacosamide was considered as add-on treatment and was started at 100 mg/day.

As Mr. A was on treatment with clozapine, his total and differential white blood cell counts were regularly monitored. After 10 days of initiation of lacosamide, he developed neutropenia with absolute neutrophil count (ANC) of 1300 cells/μl. As neutropenia is a known adverse effect of clozapine, it was stopped. However, even after 15 days of stopping clozapine, his ANC remained persistently low, reaching a nadir of 1000 cells/μl as the dose of lacosamide was increased to 200 mg/day. Suspecting lacosamide to be the causal agent, it was tapered and stopped. After 2 days of stopping lacosamide, the ANC returned to normal and remained so (>3000) for 6 months. Naranjo Adverse Drug Reaction Probability Scale[2] score was 6, indicating probable causality of lacosamide.